Returning to the issue of the cost-effectiveness of antipsychotics in the treatment of Schizophrenia

Clinical Neuropsychiatry

Volumn 5, Issue 4, 2008, Pages 184-194

  Ohlsen, Ruth I ^a,b,c   Taylor, David ^b   Tandon, Kopal ^a   Aitchison, Katherine J ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SOUTH LONDON AND MAUDSLEY NHS FOUNDATION TRUST   (United Kingdom)

^c Clinical Research Nurse   (United Kingdom)

Author keywords

Antipsychotics; Cost Effectiveness; Schizophrenia; Tolerability

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; CLOZAPINE; HALOPERIDOL; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERPHENAZINE; QUETIAPINE; RISPERIDONE; ZOTEPINE;

ADD ON THERAPY; ARTICLE; BLOOD DYSCRASIA; CLINICAL TRIAL; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE TITRATION; DRUG FATALITY; DRUG MEGADOSE; DRUG WITHDRAWAL; EXTRAPYRAMIDAL SYMPTOM; HEALTH ECONOMICS; HUMAN; METABOLIC DISORDER; METHODOLOGY; SCHIZOPHRENIA; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS; TARDIVE DYSKINESIA; WEIGHT GAIN;

EID: 57749207241     PISSN: 17244935     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (73)

1. Aitchison KJ, Kerwin RW (1997). Cost-effectiveness of clozapine. Br J Psychiatry, 171, 125-130.
2. Aitchison KJ. Meehan K, Murray RM (1999). First episode psychosis. Martin Dunitz, London.
3. Aitchison KJ, Mir A, Shivakumar K, McAllister VDM, O'Keane V, McCrone P. The cost-effectiveness of aripiprazole in an open-label add-on or switching study, under review.
4. Almond S, Knapp M, Francois C, Toumi M, Brugha T (2004). Relapse in schizophrenia: costs, clinical outcomes and quality of life. Br J Psychiatry 184, 346-51.
5. Almond S & O'Donnell O (2000). Cost analysis of the treatment of schizophrenia in the UK: a simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconom 17, 381-389.
6. Atkinson JM, Douglas-Hall P, Fischetti C, Sparshatt A, Taylor DM (2007). Outcome following clozapine discontinuation: a retrospective analysis. J Clin Psychiatry 68, 1027-1030.
7. Ascher-Svanum H, Zhu B. Faries D, Peng X, Kinon BJ, Tohen M (2008). Tardive Dyskinesia and the 3-Year Course of Schizophrenia: Results From a Large, Prospective, Naturalistic Study. J Clin Psychiatry Jun:e1-e9
8. Brown S, Inskip J, Barraclough B (2000). Causes of the excess mortality of schizophrenia. Br J Psychiatry 177, 212-217.
9. Chakrabati A, Bagnall A-M, Chue P, Fenton M, Palaniswarmy V, Wong W, Xia J (2008). Loxapine for schizophrenia. Cochrane Database of Systematic Reviews 2007, Issue 3. Art No.: CD001943. DOI:10.1002/ 14651858.CD001943 pub2.
10. Davies LM, Drummond MF (1994). Economics and schizophrenia: the real cost. Br J Psychiatry 165, Suppl 25, 18-21.
11. Davies LM, Lewis S, Jones PB, Barnes TR, Gaughran F, Hayhurst K, Markwick A, Lloyd H, CUtLASS Team (2007). Cost-effectiveness of first-v. second generation antipsychotic drugs: results from a randomized controlled trial in schizophrenia responding poorly to previous therapy. Br J Psychiatry 191, 14-22.
12. Davies LM, Barnes TRE, Jones PB, Lewis S, Gaughran F, Hayhurst K, Markwick A, Lloyd H on behalf of the CUtLASS Team (2008). A randomised controlled trial of the cost-utility of second generation antipsychotics in people with psychosis and eligible for clozapine. Value Health 11, 4, 549-62.
13. Davis JM, Matalon L, Watanabe MD, Blake I, Metalon L (1994). Depot antipsychotic drugs. Place in therapy. Drugs 47, 741-773.
14. Davis JM, Chen N, Glick ID (2003). A meta-analysis of the efficacy of second generation antipsychotics. Arch Gen Psychiatry 60, 553-64.
15. De Millas W, Lambert M, Naber D (2006). The impact of subjective well-being under neuroleptics treatment on compliance and remission. Dialogues Clin Neurosci 8, 1, 131-6.
16. Dickson RA, Dalby JT, Addington D, Williams R, McDougall GM (1999). Hospital days in risperidone-treated patients. Can J Psychiat 44, 909-913.
17. Drew LR, Griffiths KM, Hodgson DM (2002). A five year follow-up study of the use of clozapine in community practice. Aust NZ J Psychiatry 36, 6, 780-6.
18. Drummond MF & Davies L (1991). Economic analysis alongside clinical trials. Int J Technol Assess 7, 4, 4561-573.
19. Eaton WW (1991). Update on the epidemiology of schizophrenia. Epidemiolgy Rev 13, 320-328.
20. Edwards NC, Locklear JC, Rupnow MF, Diamond RJ (2005). Cost effectiveness of long-acting risperidone injection versus alternative antipsychotic agents in patients with schizophrenia in the USA. Pharmacoeconomics 23, Suppl 1, 75-89.
21. Engelhardt DM, Rosen B, Feldman J, Engelhardt JA, Cohen P (1982). A 15-year follow-up of 646 schizophrenic outpatients. Schizophr Bull 8, 493-503.
22. Essock SM, Frisman LK, Covell NH, Hargreaves WA (2000). Cost-effectiveness of clozapine compared with conventional antipsychotic medication for patients in state hospitals. Arch Gen Psychiatry 57, 987-994.
23. Fontaine KR, Heo M, Harrigan EP, Shear CL, Lakshminarayanan M, Casey DE, Allison DB (2001). Estimating the consequences of anti-psychotic induced weight gain on health and mortality rate. Psychiatry Res 101, 3, 277-88.
24. Gau SS, Chung GH, Gau CS (2008). A pharmacoeconomic analysis of atypical antipsychotics and haloperidol in first-episode schizophrenic patients in Taiwan. J Clin Psychopharmacol 28, 3, 271-8.
25. Geddes J, Freemantle N, Harrison P and Bebbington P (2000). Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 321, 1371-1376.
26. Hamilton SA, Revicki DA, Edgell ET, Genduso LA, Tollefson G (1999). Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomised clinical trial. Pharmacoeconom 15, 469-480.
27. Hargreaves S (2003). NICE guidelines address social aspect of schizophrenia. BMJ 29, 326, 679.
28. Hayhurst KP, Brown P, Lewis SW (2003). Postcode prescribing for schizophrenia. Br J Psychiatry 182, 281-83.
29. Healthcarerepublic.com. (2008) URL http://www.healthcarerepublic.com/ mims/Drug/Browse accessed 26 September 2008.
30. Heeg B, Buskens E, Botteman M, Caleo S, Ingham M, Damen J, de Charro F, vau Hout B (2008). The cost-effectiveness of a typicals in the UK. Value Health May 15.
31. Jones PB, Barnes TRE, Davies L, Dunn G, Lloyd H, Hayhurst KP, Murray RM, Markwick A, Lewis SM (2006). Randomized controlled trial of the effect on quality of 1Life of second- vs first- generation antipsychotic drugs in schizophrenia (Cost utility of the latest antipsychotic drugs in schizophrenia study) Arch Gen Psychiatry 63, 1079-1087.
32. Kelly DL, Nelson MW, Love RC, Yu Y, Conley RR (2001). Comparison of discharge rates and drug costs for patients with schizophrenia treated with risperidone or olanzapine. Psychiatr Serv 52, 676-678.
33. Kerwin RW, Millet B, Herman E, Banki CM, Lublin H, Pans M, Hanssens L, l'Italien G, McQuade RD, Beuzen JN (2007). A multicentre, randomised, naturalistic, open-label study between aripiprazole and standard of care in the management of community- treated schizophrenic patients Schizophrenic trial of aripiprazole: (STAR) study. Eur Psychiatry, 22, 7, 433-43
34. Knapp M (1997). Cost of schizophrenia. Br J Psychiatry 172, 509-518.
35. Knapp M, Windmeijer F, Brown J, Kontodimas S, Tzivilekis S, Haro JM, Ratcliffe M, Hong J, Novick D; SOHO Study Group (2008). Cost-utility analysis of treatment with olanzapine compared with other antipsychotic treatments in patients with schizophrenia in the pan-european SOHO study. Pharmacoeconomics 26, 4, 341-58.
36. Laux G, Heeg B, van Hout BA, Mehnert A (2005). Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany. Pharmacoeconomics 23, Suppl 1, 49-61.
37. Leucht S, Wahlbeck K, Hamman J, Kissling W (2003). New generation antipsychotics vs low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 36, 1581-9.
38. Lewis S, Lieberman J (2008). CATIE and Cutlass: can we handle the truth? Br J Psychiatry 192, 161-163.
39. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe RS, Davis SM, Davis CE, Lebowitz DB, Severe J, Hsiao JK; Clinical antipsychotic trials of intervention effectiveness (CATIE) investigators (2005). Effectiveness of antipsychotic drugs in patients with schizophrenia. N Engl J Med 22, 353, 12, 1209-23.
40. Llorca PM, Miadi-Fargier H, Lançon C, Jasso Mosqueda G, Casadebaig F, Phillipe A, Guillon P, Mehnert A, Omnès LF, Chicoye A, Durand-Zaleski I (2005). Cost-effectiveness analysis of schizophrenic patient care settings: impact of an atypical antipsychotic under long-acting injection formulation. Encephale 31, 2, 235-46.
41. Lynch J, Morrison J, Graves N, Meddis D, Drummond MF, Hellewell JSE (2001). The health economic implications of treatment with quetiapine: an audit of long-term treatment for patients with chronic schizophrenia. Eur Psychiat 16, 307-312.
42. McEvoy JP, Hogarty GE, Steingard S (1991). Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. Arch Gen Psychiatry 48, 739-745.
43. McGrath J, Saha S, Chant D, Welham J (2008). A concise overview of incidence, prevalence and mortality. Epidemiol Rev Jun 14 (epub ahead of print) doi:10.1093/epirev/mxn001.
44. McGuire TG (1991). Measuring the economic costs of schizophrenia. Schizophr Bull 17, 375-388.
45. Mangalore R, Knapp M (2007). Cost of schizophrenia in England. Ment Health Policy Econ 10, 1, 23-41.
46. Marder SR (2000). Integrating pharmacological and psychosocial treatments for schizophrenia. Acta Psychiatr Scand, Suppl 407, 87-90.
47. Miller DD, McEvoy JP, Davis SM, Caroff SN, Saltz BL, Chakos MH, Swartz MS, Keefe RS, Rosenheck RA, Stroup TS, Lieberman JA (2005), Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res 80, 1, 33-43.
48. Nightengale BS, Crumly JM, Liao J, Lawrence BJ, Jacobs EW (1998). Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone. Current Topics Clin Psychopharm 34, 373-382.
49. O'Brien A (2004). Starting clozapine in the community: a UK perspective. CNS Drugs 18, 13, 845-52.
50. Obradovic M, Mrhar A, Kos M (2007). Cost-effectiveness of antipsychotic for outpatients with schizophrenia. Int J Clin Pract 61, 12, 1979-88.
51. Olivares JM, Rodriguez-Martinez A, Buàon JA, Alonso-Escalano D, Rodriguez-Morales A; on behalf of the e-STAR Study Group (2008). Cost-effectiveness analysis of switching antipsychotic medication to long-acting injectable risperidone in patients with schizophrenia: a 12- and 24-month follow-up from the e-STAR database in Spain. Appl Health Econ Health Policy 6, 1, 41-53.
52. Patel MX, DeZoysa N, Bernadt M, David A (2008). Depot and oral antipsychotics: patient preferences and attitudes are not the same thing. J Psychopharmacol 026988110809214v1
53. Procyshyn RM & Zerjav S (1998). Drug utilization patterns and outcomes associated with in-patient treatment with risperidone or olanzapine. Clin Ther 20, 1203-1217.
54. Rabinowitz J, Lichtenberg P, Kaplan Z (2000). Comparison of cost, dosage and clinical preference for risperidone and olanzapine. Schizophr Res 46, 2-3, 91-96.
55. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE (1992). The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull 18, 185-207.
56. Rice DP (1999) The economic impact of schizophrenia. J Clin Psychiatry 60, 1, 4-6.
57. Rocca P, Crivelli B, Marino F, Mongini T, Portaleone F, Bogetto F (2008). Correlations of attitudes towards antipsychotic drugs with insight and objective psychopathology in schizophrenia. Compr Psychiatry 49, 2, 170-6.
58. Rosenheck R, Chamber J, Xu W, Thomas J, Henderson W, Frisman L, Fye C, Charney D (1997). A comparison of clozapine and haloperidol in hospitalized patients with refractory schizophrenia. New Engl J Med 337, 809-815.
59. Rosenheck R, Cramer J, Allan E, Erdos J, Frisman LK, Xu W, Thomas J, Henderson W, Charney D (1999). Cost-effectiveness of clozapine in patients with high and low levels of hospital use. Arch Gen Psychiatry 56, 565-572.
60. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Lin H, Scott Stroup T, McEvoy J, Davis SM, Keefe RSE. Swartz M, Perkins DO, Hsaio JK, Lieberman J for the CATIE Study Investigators (2006). Cost-effectiveness of second generation antipsychotics and perphenazine in a randomised trial of treatment for chronic schizophrenia. Am J Psychiatry 163, 12, 2080-89.
61. Rosenheck RA, Leslie DL, Busch S, Rofman ES, Sernyak M (2008). Rethinking antipsychotic formulary policy. Schizophr Bull 34, 2, 375-80.
62. Rössler W, Salize HJ, van Os J, Reicher-Rössler A (2005). Size of burden of schizophrenia and psychotic disorders. Eur Neuropsychopharmacol 15, 4, 399-409.
63. Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA (2008). Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ 11, 2, 89-97.
64. Taylor D, Aitchison KJ (1999). The pharmaco-economics of atypical antipsychotics. Int J Psychiat Clin 3, 237-248.
65. Tandon K, Aitchison KJ (2002). The cost-effectiveness of atypical versus typical antipsychotics. Psychiatry 1, 10, 66-69.
66. Taylor DM, Wright T, Libretto SA, for the Risperidone Olanzapine Drug Outcomes Studies in Schizophrenia (RODOS) UK Investigator Group (2003). Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis. J Clin Psychiatry 64, 5, 589-597.
67. Taylor D, Hayhurst K, Kerwin R (2007a). A controlled, mirror-image study of second-generation antipsychotics in the treatment of schizophrenia. Int Clin Psychopharmacol 22, 3, 133-6.
68. Taylor D, Atkinson J, Fischetti C, Sparshatt A, Jones S (2007b). A prospective 6-month analysis of the naturalistic use of aripiprazole - factors predicting favourable outcome. Acta Psychiatr Scand 116, 461-466.
69. Taylor D, Fischetti C, Sparshatt A, Thomas A, Bishara D, Cornelius V (in press). Risperidone long-acting injection: a 6-year mirror-image study of healtcare resource use. J Clin Psychiatry.
70. Tollefson GD, Beasley CM Jr, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA Thieme ME (1997). Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 154, 4, 457-465.
71. Van Os J, Fahy T, Jones P, Harvey I, Sham P, Lewis S, Bebbington P, Toone B, Williams M, Murray R (1996). Psychopathological syndromes in the functional psychoses: associations with course and outcome. Psychol Med 26, 161-176.
72. Wang C, Kennedy J, Cohen LC, Sclar DA (2008). Coverage of atypical antipsychotics among Medicare drug plans in the state of Washington for fiscal year 2007. Prim Care Companion J Clin Psychiatry 10, 4, 313-317.
73. Young CL, Taylor DM (2006). Healthcare resource utilization associated with switching to risperidone long-acting injection. Acta Psychiatr Scand 114, 1, 14-20.